Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

10 Dec 2019

Abstract excerpt

Acute graft-versus-host disease (aGVHD) remains a significant complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vedolizumab could help prevent aGVHD by inhibiting the migration of both naive and activated lymphocytes into gut-associated lymphoid tissues and the lamina propria. We carried out a phase 1b, open-label, dose-finding study in adults undergoing allo-HSCT to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation
Share to Immunotherapy and Immune Responses
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31821456
DOI: 10.1182/bloodadvances.2019000893

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantationPMID 31821456Read ↗

Concise Review: Acute Graft-Versus-Host Disease: Immunobiology, Prevention, and TreatmentSemantic proximity Read ↗

Emerging novel therapies for steroid-refractory acute graft-versus-host disease: recent advances and future directionsSemantic proximity Read ↗

Defibrotide inhibits donor leucocyte‐endothelial interactions and protects against acute graft‐versus‐host diseaseSemantic proximity Read ↗

Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationSemantic proximity Read ↗

Graft-versus-host diseaseSemantic proximity Read ↗

The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Evaluating Axatilimab as a treatment option for chronic graft-versus-host diseaseSemantic proximity Read ↗

Emerging Therapeutics for the Control of Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

New molecules in the therapy of chronic graft-versus-host diseaseSemantic proximity Read ↗

Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipientsSemantic proximity Read ↗

Extracellular vesicles: a new frontier in diagnosing and treating graft-versus-host disease after allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.